Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats

  • Authors:
    • Chi-Hua Guo
    • Lu Bai
    • Huang-Hui Wu
    • Jing Yang
    • Guo-Hong Cai
    • Si-Xiang Zeng
    • Xin Wang
    • Sheng-Xi Wu
    • Wei Ma
  • View Affiliations

  • Published online on: November 10, 2016     https://doi.org/10.3892/or.2016.5241
  • Pages: 249-258
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Analgesic strategy of a single drug analgesia in bone cancer pain (BCP) has shifted to combined analgesia with different drugs which have different mechanism. After tumor cell inculation, the activation of signal transducer and activator of transcription (STAT3) and extracellular signal-regulated kinase (ERK) signaling pathway are involved in the development and maintenance of BCP, whereas a decrease in the expression of spinal STAT3 and ERK through using their specific blocker, lead to attenuation of BCP. Hence, in this study, we clarified that intrathecal (i.t.) injection of midazolam (MZL) and ropivacaine (Ropi) induces synergistic analgesia on BCP and is accompanied with different mechanisms of these analgesic effect. Hargreaves heat test was used to detect the analgesic effect of single dose of i.t. MZL, Ropi and their combination on the BCP rats. At consecutive daily administration experiment, thermal hyperalgesia was recorded, and immunohistochemical staining was used to detect the expression of c-Fos, spinal glial fibrillary acidic protein (GFAP) and ionized calcium binding adapter molecule-1 (IBA-1). Then, western blot analysis was used to examine spinal TSPO, GFAP, IBA-1, pERK/ERK and pSTAT3/STAT3 levels on day 14 after tumor cell inoculation. i.t. MZL or Ropi showed a short-term analgesia dose-dependently, and MZL displayed better effect on inhibition of pSTAT3 expression than pERK, but Ropi was just the reverse, then consecutive daily administrations of their combination acted synergistically to attenuate thermal hyperalgesia with downregulated spinal ‘neuron-astrocytic activation’ in the BCP rats. i.t. co-delivery of MZL and Ropi shows synergistic analgesia on the BCP with the inhibition of spinal ‘neuron-astrocytic activation’. Spinal different signaling pathway inhibition for MZL and Ropi may be involved in this process.
View Figures
View References

Related Articles

Journal Cover

January-2017
Volume 37 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo C, Bai L, Wu H, Yang J, Cai G, Zeng S, Wang X, Wu S and Ma W: Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats. Oncol Rep 37: 249-258, 2017
APA
Guo, C., Bai, L., Wu, H., Yang, J., Cai, G., Zeng, S. ... Ma, W. (2017). Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats. Oncology Reports, 37, 249-258. https://doi.org/10.3892/or.2016.5241
MLA
Guo, C., Bai, L., Wu, H., Yang, J., Cai, G., Zeng, S., Wang, X., Wu, S., Ma, W."Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats". Oncology Reports 37.1 (2017): 249-258.
Chicago
Guo, C., Bai, L., Wu, H., Yang, J., Cai, G., Zeng, S., Wang, X., Wu, S., Ma, W."Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats". Oncology Reports 37, no. 1 (2017): 249-258. https://doi.org/10.3892/or.2016.5241